JP2006524491A5 - - Google Patents

Download PDF

Info

Publication number
JP2006524491A5
JP2006524491A5 JP2006503972A JP2006503972A JP2006524491A5 JP 2006524491 A5 JP2006524491 A5 JP 2006524491A5 JP 2006503972 A JP2006503972 A JP 2006503972A JP 2006503972 A JP2006503972 A JP 2006503972A JP 2006524491 A5 JP2006524491 A5 JP 2006524491A5
Authority
JP
Japan
Prior art keywords
tropomyosin
compound
activity
binding
cell surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006503972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006524491A (ja
Filing date
Publication date
Priority claimed from AU2003901316A external-priority patent/AU2003901316A0/en
Application filed filed Critical
Publication of JP2006524491A publication Critical patent/JP2006524491A/ja
Publication of JP2006524491A5 publication Critical patent/JP2006524491A5/ja
Withdrawn legal-status Critical Current

Links

JP2006503972A 2003-03-21 2004-03-22 細胞表面タンパク質の調節 Withdrawn JP2006524491A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003901316A AU2003901316A0 (en) 2003-03-21 2003-03-21 Regulation of cell surface proteins
PCT/AU2004/000358 WO2004082690A1 (en) 2003-03-21 2004-03-22 Regulation of cell surface proteins

Publications (2)

Publication Number Publication Date
JP2006524491A JP2006524491A (ja) 2006-11-02
JP2006524491A5 true JP2006524491A5 (https=) 2007-05-24

Family

ID=31500359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503972A Withdrawn JP2006524491A (ja) 2003-03-21 2004-03-22 細胞表面タンパク質の調節

Country Status (7)

Country Link
US (1) US20060263781A1 (https=)
EP (1) EP1622626A1 (https=)
JP (1) JP2006524491A (https=)
CN (1) CN1761472A (https=)
AU (1) AU2003901316A0 (https=)
CA (1) CA2517186A1 (https=)
WO (1) WO2004082690A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5140218B2 (ja) 2001-09-14 2013-02-06 有限会社コヒーレントテクノロジー 表面洗浄・表面処理に適した帯電アノード水の製造用電解槽及びその製造法、並びに使用方法
CA2468856C (en) 2001-12-05 2011-07-26 Osao Sumita Method and apparatus for producing negative and positive oxidative reductive potential (orp) water
US9168318B2 (en) 2003-12-30 2015-10-27 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and methods of using the same
CA2602522C (en) 2005-03-23 2014-09-09 Oculus Innovative Sciences, Inc. Method of treating skin ulcers using oxidative reductive potential water solution
BRPI0610901B1 (pt) 2005-05-02 2019-04-16 Oculus Innovative Sciences, Inc. Uso de uma solução aquosa de potencial oxi-redutivo (orp).
EP1993571B1 (en) 2006-01-20 2018-07-25 Sonoma Pharmaceuticals, Inc. Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
JP5175336B2 (ja) * 2007-04-16 2013-04-03 モメンタ ファーマシューティカルズ インコーポレイテッド 細胞表面グリコシル化に関連する方法
WO2010148004A1 (en) 2009-06-15 2010-12-23 Oculus Innovative Sciences, Inc. Solution containing hypochlorous acid and methods of using same
CA2811699C (en) * 2010-09-28 2019-07-02 Abera Bioscience Ab Fusion protein for secretory protein expression
CA3116015A1 (en) * 2018-10-30 2020-05-07 University Of Florida Research Foundation, Incorporated Amino acid compositions and methods for treating cystic fibrosis
CN111175431A (zh) * 2020-01-15 2020-05-19 上海林志生物科技有限公司 一种用于肺癌诊断的靶蛋白及其用途、试剂盒
CN113588942B (zh) * 2021-07-01 2022-04-19 浙江大学 一种检测抗原肌球蛋白1-IgG抗体的试剂盒

Similar Documents

Publication Publication Date Title
Goh et al. The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin
EP2569431B1 (en) Methods for identifying compounds which modulate interleukins 17 and 23 signaling activity
Bivalacqua et al. Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of in vivo gene therapy of anti-arginase
CN101573446B (zh) 针对中期因子的适体及其应用
Xia et al. Suppression of renal tubulointerstitial fibrosis by small interfering RNA targeting heat shock protein 47
JP6141018B2 (ja) 炎症性障害を治療するための分子
CN112040988A (zh) 修饰的aav衣壳多肽用于治疗肌肉疾病
JP2006524491A5 (https=)
CN115175685B (zh) 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸
JP2007516714A5 (ja) 間葉系前駆細胞の骨芽細胞への分化を誘導する化合物の同定方法
CN120500349A (zh) 包含抗体切割酶的组合物及其使用方法
JP2010521978A5 (https=)
JP2021531038A5 (https=)
CN108642069A (zh) 一种三疣梭子蟹comt基因及其应用
McCollum et al. Safety and biodistribution of nanoligomers targeting the SARS-CoV-2 genome for the treatment of COVID-19
JP2010536365A5 (https=)
WO2016079321A1 (en) Antagonists of setdb2 for use in the therapy of infectious diseases
US20240392295A1 (en) Treatment of mst1 related diseases and disorders
JP7626423B6 (ja) 線維症治療薬
JP2007525203A5 (https=)
Uemura et al. Short polymers of arginine rapidly translocate into vascular cells effects on nitric oxide synthesis
DE602005026834D1 (de) Verwendung von gilz-protein zur modulation einer antigenspezifischen immunantwort
US12442002B2 (en) RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use
Kramer et al. Knockdown of Fcγ receptor III in an arthritic temporomandibular joint reduces the nociceptive response in rats
JP2005536535A5 (https=)